Program in Chemical Biology, Department of Chemical Physiology and Biochemistry, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, United States.
Methods Enzymol. 2020;633:169-184. doi: 10.1016/bs.mie.2019.11.002. Epub 2019 Nov 22.
The cyclic-AMP response element binding protein (CREB) is an important nuclear transcription factor and has been shown to be overexpressed and/or over-activated in many different cancer types, suggesting that targeting CREB is a novel approach for developing cancer therapies. Our lab discovered the first cell-permeable small molecule inhibitor of CREB, from which we further developed a potent CREB inhibitor with in vivo anti-cancer activity. In this article, we detailed our biochemical and cell-based bioassays to assess different small molecule CREB inhibitors.
环腺苷酸反应元件结合蛋白(CREB)是一种重要的核转录因子,已在许多不同类型的癌症中显示出过表达和/或过度激活,表明靶向 CREB 是开发癌症疗法的一种新方法。我们的实验室发现了第一个细胞通透性的 CREB 小分子抑制剂,在此基础上,我们进一步开发了一种具有体内抗癌活性的强效 CREB 抑制剂。在本文中,我们详细介绍了我们用于评估不同小分子 CREB 抑制剂的生化和基于细胞的生物测定。